Unibest
← Back to patent-cliff list

CAS 3886-69-9

(R)-1-phenylethan-1-amine(R)-(-)-1-Phenylethylamine

Codes: ATOR-012, Tamsulosin Hydrochloride-002, ROSU-039, FINA-034, SITAF-010, MITI-013

Application context (from source-drug indications)

Type 2 diabetesAtorvastatin Calcium Hydrate/Metformin HydrochlorideHyperlipidaemiaAtorvastatin Calcium Hydrate/Metformin HydrochlorideErectile dysfunctionTadalafil/TamsulosinBenign prostatic hyperplasiaTadalafil/TamsulosinHypertensionFimasartan potassium trihydrate/Rosuvastatin calciumDyslipidaemiaFimasartan potassium trihydrate/Rosuvastatin calciumHypertensionRosuvastatin Calcium/TelmisartanHyperlipidaemiaRosuvastatin Calcium/TelmisartanOtitis externaFinafloxacinOtitis media with effusionFinafloxacinOtitis mediaFinafloxacinUrinary tract infectionFinafloxacinPyelonephritisFinafloxacinGram-negative bacterial infectionFinafloxacinHypertensionAtorvastatin Calcium Hydrate/IrbesartanHyperlipidaemiaAtorvastatin Calcium Hydrate/IrbesartanLower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideHypercholesterolaemiaAtorvastatin Calcium Hydrate/RamiprilHypertensionAtorvastatin Calcium Hydrate/RamiprilCystitisSitafloxacin HydrateSinusitisSitafloxacin HydrateTonsillitisSitafloxacin HydratePneumoniaSitafloxacin HydrateCervicitisSitafloxacin HydratePericoronitisSitafloxacin HydrateHyperlipoproteinaemia type IIIAtorvastatin Calcium HydrateHyperlipidaemiaAtorvastatin Calcium HydrateHeterozygous familial hypercholesterolaemiaAtorvastatin Calcium HydrateHeart failureAtorvastatin Calcium HydrateType 2 diabetesAtorvastatin Calcium HydrateStrokeAtorvastatin Calcium HydrateBenign prostatic hyperplasiaTamsulosin HydrochlorideUrinary tract infectionTamsulosin HydrochlorideUrinary retentionTamsulosin HydrochlorideInguinal herniaTamsulosin HydrochlorideVoiding dysfunctionTamsulosin HydrochlorideLower urinary tract symptomsTamsulosin HydrochlorideHomozygous familial hypercholesterolaemiaRosuvastatin CalciumHeterozygous familial hypercholesterolaemiaRosuvastatin CalciumHyperlipoproteinaemia type IIIRosuvastatin CalciumAtherosclerosisRosuvastatin CalciumHyperlipoproteinaemia type IIRosuvastatin CalciumHypercholesterolaemiaRosuvastatin CalciumType 2 diabetesMitiglinideDiabetesMitiglinide

Source drugs (routes using this intermediate)

DrugTierExpiry
Atorvastatin Calcium Hydrate/Metformin HydrochlorideTier C — Watch / trade-
Tadalafil/TamsulosinTier C — Watch / trade-
Fimasartan potassium trihydrate/Rosuvastatin calciumTier C — Watch / trade-
Rosuvastatin Calcium/TelmisartanTier C — Watch / trade-
FinafloxacinTier C — Watch / trade-
Atorvastatin Calcium Hydrate/IrbesartanTier C — Watch / trade-
Solifenacin Succinate/Tamsulosin HydrochlorideTier C — Watch / trade-
Dutasteride/Tamsulosin HydrochlorideTier C — Watch / trade-
Atorvastatin Calcium Hydrate/RamiprilTier C — Watch / trade-
Sitafloxacin HydrateTier C — Watch / trade-
Atorvastatin Calcium HydrateTier B — Position early-
Tamsulosin HydrochlorideTier C — Watch / trade-
Rosuvastatin CalciumTier B — Position early-
MitiglinideTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

FinafloxacinOptimised routesteps: 24total yield: 21 g
2,4-dichloro-3-cyano-5-fluorobenzoyl chloride→(Z)-ethyl 3-(dimethylamino)acrylate→ethyl 2-(2,4-dichloro-3-cyano-5-fluorobenzoyl)-3-(dimethylamino)acrylate→cyclopropanamine→ethyl 3-(cyclopropylamino)-2-(2,4-dichloro-3-cyano-5-fluorobenzoyl)acrylate→ethyl 7-chloro-8-cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate→(E)-but-2-ene-1,4-diol→1-tosyl-2,5-dihydro-1H-pyrrole→3-tosyl-6-oxa-3-azabicyclo[3.1.0]hexane→2,4-dichloro-1-fluorobenzene→1-(2,4-dichloro-5-fluorophenyl)ethanone→2,4-dichloro-5-fluorobenzoic acid→2,4-dichloro-5-fluoro-3-nitrobenzoic acid→methyl 2,4-dichloro-5-fluoro-3-nitrobenzoate→methyl 3-amino-2,4-dichloro-5-fluorobenzoate→methyl 2,4-dichloro-3-cyano-5-fluorobenzoate→2,4-dichloro-3-cyano-5-fluorobenzoic acid→(4aS,7aS)-tert-butyl hexahydropyrrolo[3,4-b][1,4]oxazine-4(4aH)-carboxylate→(4aS,7aS)-tert-butyl 6-(8-cyano-1-cyclopropyl-3-(ethoxycarbonyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)hexahydropyrrolo[3,4-b][1,4]oxazine-4(4aH)-carboxylate→7-((4aS,7aS)-4-(tert-butoxycarbonyl)hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl)-8-cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid→(E)-1,4-dichlorobut-2-ene→(R)-1-phenylethan-1-amine→(3S,4S)-4-(((R)-1-phenylethyl)amino)-1-tosylpyrrolidin-3-ol→2-chloroacetyl chloride→2-chloro-N-((3S,4S)-4-hydroxy-1-tosylpyrrolidin-3-yl)-N-((R)-1-phenylethyl)acetamide→(4aS,7aS)-4-((R)-1-phenylethyl)-6-tosylhexahydropyrrolo[3,4-b][1,4]oxazin-3(2H)-one→(4aS,7aS)-4-((R)-1-phenylethyl)-6-tosyloctahydropyrrolo[3,4-b][1,4]oxazine→(4aS,7aS)-6-tosyloctahydropyrrolo[3,4-b][1,4]oxazine→(4aS,7aS)-tert-butyl 6-tosylhexahydropyrrolo[3,4-b][1,4]oxazine-4(4aH)-carboxylate

Intermediates available on this site

Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.

SupplierProductPrice bandMOQLead timeQualificationsAction
Unibest Nantong cGMP SiteCarbamic acid, (7S)-5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)
Pharmaceutical Intermediates
On requestOn requestOn request
—

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.